Key result
The ePAD trial is a randomized, open-label study designed to evaluate edoxaban versus clopidogrel (both with aspirin) in 203 patients with PAD after endovascular intervention; results are pending.
Why the study?
Does edoxaban plus aspirin improve safety and efficacy compared to clopidogrel plus aspirin in patients with peripheral artery disease after femoropopliteal endovascular intervention?
Population
203 patients from 7 countries with peripheral artery disease after femoropopliteal endovascular intervention
Comparison
Edoxaban 60 mg once daily for 3 months combined… vs Clopidogrel 75 mg/d for 3 months combined with…
Design
Review, randomized, open-label, outcomes assessed and adjudicated centrally in…
Follow-up
6 months
Authors
Loading...
The ePAD study is designed to evaluate the safety and efficacy of edoxaban plus aspirin versus clopidogrel plus aspirin after femoropopliteal endovascular intervention.
RCT (n=203)
Open-label
Randomized
Yes
Does edoxaban plus aspirin improve safety and efficacy compared to clopidogrel plus aspirin in patients with peripheral artery disease after femoropopliteal endovascular intervention?
The ePAD study is designed to evaluate the safety and efficacy of edoxaban plus aspirin versus clopidogrel plus aspirin after femoropopliteal endovascular intervention.
Tangelder et al. (2015) conducted an RCT in Peripheral Artery Disease (n=203). Edoxaban vs. Clopidogrel 75 mg/d for 3 months (plus aspirin 100 mg/d for 6 months) was evaluated on Major or clinically relevant nonmajor bleeding (safety); restenosis or reocclusion at the treated segment(s) (efficacy). The ePAD trial is a randomized, open-label study designed to evaluate edoxaban versus clopidogrel (both with aspirin) in 203 patients with PAD after endovascular intervention; results are pending.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: